HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

SPF Claims No More Reliable In 2018 Than Previous Years – Consumer Reports

This article was originally published in The Rose Sheet

Executive Summary

The nonprofit publication’s 2018 sunscreen ratings and buying guide reflect its own SPF testing in which a third of sunscreens again underperformed dramatically compared with labeled SPFs. Low-scoring brands may face a new wave of false-advertising litigation, with many related suits still pending in federal and state courts.

You may also be interested in...



Consumer Reports Issues 2019 Sunscreen Recommendations; All Contain Oxybenzone

While acknowledging concerns about oxybenzone, Consumer Reports maintains the importance of sunscreen to help prevent skin cancer and says oxybenzone-containing offerings continue to test best when it comes to broad-spectrum protection and minimal SPF “variation.”

SPF Fraud Cases Hard To Shake, Could Shine Light On FDA Protocol Problems

As SPF defendants’ dismissal motions continue to be shot down in federal courts, it increasingly seems that their SPF claims and the radically different test results alleged by plaintiffs will have to be subjected to rigorous analysis and expert opinion, undertakings that could shine light on inherent problems with FDA’s testing protocol rather than overt moves by companies to inflate the protective capacity of their products.

Suns Sets In Hawaii On Sunscreens Containing Octinoxate, Oxybenzone

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS121618

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel